) Genetic and cytogenetic studies involving large panels of tumor cases have identified a set of chromosomal deletions that are recurrent in multiple tumor types, suggesting that they may involve tumor suppressor genes of general relevance in tumorigenesis. The goal of this research program is to identify the tumor suppressor genes that are altered in two of these chromosomal alterations and to elucidate their role in tumorigenesis: Project 1 will identify the gene involved in chromosome 6q27 deletions that are associated with non-Hodgkin's lymphoma, breast and ovarian carcinoma, renal carcinoma and, possibly, melanoma. Project 2 will elucidate the normal function and role in tumorigenesis of PTEN, the recently identified gene coding for a tyrosine phosphatase and involved in chromosome 10q23 deletions associated with breast cancer, including both sporadic and familial cases, glioblastoma, prostate cancer, endometrial cancer, and non-Hodgkin's lymphoma. Project 3 will focus on mouse models in which alterations of the familial breast cancer genes BRCA-1 and BRCA-2 will be studied for their effects on development and tumorigenesis, either alone or in combination with other genetic and epigenetic alterations involved in tumor progression. These studies will be supported by an Administrative Core. The long term goal of this Program Project is to exploit the identified genetic alterations for a better understanding of the pathogenesis of cancer. In addition, the genetic lesions identified in this project should prove useful clinically as markers for improved diagnosis and, eventually as targets for rational therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA075553-04
Application #
6376530
Study Section
Subcommittee G - Education (NCI)
Program Officer
Okano, Paul
Project Start
1998-07-15
Project End
2003-04-30
Budget Start
2001-05-01
Budget End
2003-04-30
Support Year
4
Fiscal Year
2001
Total Cost
$1,280,222
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Politi, Katerina; Szabolcs, Matthias; Fisher, Peter et al. (2004) A mouse model of uterine leiomyosarcoma. Am J Pathol 164:325-36
Politi, Katerina; Kljuic, Ana; Szabolcs, Matthias et al. (2004) 'Designer' tumors in mice. Oncogene 23:1558-65
Mason, Jeffrey L; Xuan, Shouhong; Dragatsis, Ioannis et al. (2003) Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J Neurosci 23:7710-8
Chiao, Eric; Fisher, Peter; Crisponi, Laura et al. (2002) Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev Biol 243:185-206
Zhang, Mei; Xuan, Shouhong; Bouxsein, Mary L et al. (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-12
Podsypanina, K; Lee, R T; Politis, C et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-5
Ludwig, T; Fisher, P; Ganesan, S et al. (2001) Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 15:1188-93
Simpson, L; Li, J; Liaw, D et al. (2001) PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol Cell Biol 21:3947-58
Ludwig, T; Fisher, P; Murty, V et al. (2001) Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20:3937-48
Dietrich, P; Dragatsis, I; Xuan, S et al. (2000) Conditional mutagenesis in mice with heat shock promoter-driven cre transgenes. Mamm Genome 11:196-205

Showing the most recent 10 out of 13 publications